Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Disease-relevant autoantibodies in first episode schizophrenia.

Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR.

J Neurol. 2011 Apr;258(4):686-8. doi: 10.1007/s00415-010-5788-9. Epub 2010 Oct 26. No abstract available.

2.

Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies.

de Witte LD, Hoffmann C, van Mierlo HC, Titulaer MJ, Kahn RS, Martinez-Martinez P; European Consortium of Autoimmune Mental Disorders (CAIMED)..

JAMA Psychiatry. 2015 Jul;72(7):731-3. doi: 10.1001/jamapsychiatry.2015.0526. No abstract available.

PMID:
25970159
3.

Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia.

Masdeu JC, González-Pinto A, Matute C, Ruiz De Azúa S, Palomino A, De Leon J, Berman KF, Dalmau J.

Am J Psychiatry. 2012 Oct;169(10):1120-1. doi: 10.1176/appi.ajp.2012.12050646. No abstract available.

4.

[Anti-NR1 antibodies in anti-N-methyl-D-aspartate receptor encephalitis and schizophrenia].

Le Guen E, Doukhan R, Hamdani N, Tamouza R, Groc L, Honnorat J, Leboyer M.

Med Sci (Paris). 2015 Jan;31(1):60-7. doi: 10.1051/medsci/20153101014. Epub 2015 Feb 6. Review. French.

5.

Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia.

Rhoads J, Guirgis H, McKnight C, Duchemin AM.

Schizophr Res. 2011 Jul;129(2-3):213-4. doi: 10.1016/j.schres.2010.12.018. Epub 2011 Feb 1. No abstract available.

PMID:
21277743
6.

Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited.

Steiner J, Teegen B, Schiltz K, Bernstein HG, Stoecker W, Bogerts B.

JAMA Psychiatry. 2014 Jul 1;71(7):838-9. doi: 10.1001/jamapsychiatry.2014.469. No abstract available.

PMID:
24871043
7.

N-Methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders.

Steiner J, Bogerts B.

Schizophr Res. 2015 Mar;162(1-3):291. doi: 10.1016/j.schres.2015.01.009. Epub 2015 Jan 15. No abstract available.

PMID:
25600550
8.

Response to Steiner and Bogerts on N-methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders.

Pearlman DM, Najjar S.

Schizophr Res. 2015 Mar;162(1-3):292-3. doi: 10.1016/j.schres.2015.01.007. Epub 2015 Feb 4. No abstract available.

PMID:
25660466
9.

Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis.

Deakin J, Lennox BR, Zandi MS.

Biol Psychiatry. 2014 Feb 15;75(4):284-91. doi: 10.1016/j.biopsych.2013.07.018. Epub 2013 Aug 26. Review.

PMID:
23988024
10.

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A.

Brain. 2010 Jun;133(Pt 6):1655-67. doi: 10.1093/brain/awq113.

11.

Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder.

Pearlman DM, Najjar S.

Schizophr Res. 2014 Aug;157(1-3):249-58. doi: 10.1016/j.schres.2014.05.001. Epub 2014 Jun 2. Review.

12.

Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis.

Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, Kästner A, Skalej M, Jordan W, Schiltz K, Klingbeil C, Wandinger KP, Bogerts B, Stoecker W.

JAMA Psychiatry. 2013 Mar;70(3):271-8. doi: 10.1001/2013.jamapsychiatry.86.

PMID:
23344076
13.

Antibody-mediated encephalitis: a treatable cause of schizophrenia.

Lennox BR, Coles AJ, Vincent A.

Br J Psychiatry. 2012 Feb;200(2):92-4. doi: 10.1192/bjp.bp.111.095042.

14.

Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis.

Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS.

Psychol Med. 2014 Sep;44(12):2475-87. doi: 10.1017/S003329171300295X. Epub 2013 Dec 13. Review. Erratum in: Psychol Med. 2014 Sep;44(12):2488.

PMID:
24330811
15.

Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin.

Prüss H, Dalmau J, Harms L, Höltje M, Ahnert-Hilger G, Borowski K, Stoecker W, Wandinger KP.

Neurology. 2010 Nov 9;75(19):1735-9. doi: 10.1212/WNL.0b013e3181fc2a06.

PMID:
21060097
16.

Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children.

Pathmanandavel K, Starling J, Merheb V, Ramanathan S, Sinmaz N, Dale RC, Brilot F.

Biol Psychiatry. 2015 Mar 15;77(6):537-47. doi: 10.1016/j.biopsych.2014.07.014. Epub 2014 Jul 23.

PMID:
25168608
17.

Neurological picture. Anti-NMDA-receptor encephalitis: unusual presentation of an uncommon condition.

Reid DK, Clardy SL.

J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):69-70. doi: 10.1136/jnnp-2012-302904. Epub 2012 Sep 5. No abstract available.

PMID:
22952330
18.

[Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia].

Govorin NV, Vasil'eva AI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(3):54-7. Russian.

PMID:
21423116
19.

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.

Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J.

Ann Neurol. 2009 Jul;66(1):11-8. doi: 10.1002/ana.21756.

20.

Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia.

Senda M, Bessho K, Oshima E, Sakamoto S, Tanaka K, Tsutsui K, Kanbayashi T, Takaki M, Yoshimura B.

J Clin Psychopharmacol. 2016 Feb;36(1):92-3. doi: 10.1097/JCP.0000000000000439. No abstract available.

PMID:
26658265

Supplemental Content

Support Center